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Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the
context of impaired glucose tolerance, but its effects in the setting of acute myocardial
infarction (MI) are unknown. We determined whether metformin administration affects lipo-
protein subfractions 4 months after ST-segment elevation MI (STEMI). Second, we
assessed associations of lipoprotein subfractions with left ventricular ejection fraction
(LVEF) and infarct size 4 months after STEMI.
Methods
371 participants without known diabetes participating in the GIPS-III trial, a placebo con-
trolled, double-blind randomized trial studying the effect of metformin (500 mg bid) during 4
months after primary percutaneous coronary intervention for STEMI were included of whom
317 completed follow-up (clinicaltrial.gov Identifier: NCT01217307). Lipoprotein subfrac-
tions were measured using nuclear magnetic resonance spectroscopy at presentation, 24
hours and 4 months after STEMI. (Apo)lipoprotein measures were obtained during acute
STEMI and 4 months post-STEMI. LVEF and infarct size were measured by cardiac mag-
netic resonance imaging.
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Results
Metformin treatment slightly decreased LDL cholesterol levels (adjusted P = 0.01), whereas
apoB remained unchanged. Large LDL particles and LDL size were also decreased after
metformin treatment (adjusted P<0.001). After adjustment for covariates, increased small
HDL particles at 24 hours after STEMI predicted higher LVEF (P = 0.005). In addition,
increased medium-sized VLDL particles at the same time point predicted a smaller infarct
size (P<0.001).
Conclusion
LDL cholesterol and large LDL particles were decreased during 4 months treatment with
metformin started early after MI. Higher small HDL and medium VLDL particle concentra-
tions are associated with favorable LVEF and infarct size.
Introduction
The clinical relevance of plasma lipids and lipoprotein levels in predicting (recurrent) coronary
heart disease is well appreciated [1]. Indeed, pharmacological treatment aimed at lowering low
density lipoprotein (LDL) cholesterol is an essential part of the routine care of patients with a
history of myocardial infarction (MI) [2]. Importantly, lipoprotein particles are highly hetero-
geneous in size, structure and function with probable consequences for cardiovascular risk pre-
diction [3–10]. In the non-acute setting, LDL and high density lipoprotein (HDL) particle
characteristics have been proposed to be more closely associated with (incident) coronary
heart disease compared to LDL cholesterol and HDL cholesterol concentrations [3–5,7–9,11–
21]. When determined at presentation of MI, LDL cholesterol, HDL cholesterol and triglycer-
ides have been variably shown to predict recurrent adverse cardiac events [10]. However, little
is currently known about the prognostic value of lipoprotein subfraction characteristics
obtained in the setting of an acute MI.
In subjects with impaired glucose tolerance, metformin administration modestly reduces
the LDL particle concentration, and concomitantly decreases small dense LDL particles and
increases small HDL particles, as determined by nuclear magnetic resonance (NMR) spectrom-
etry [22]. Furthermore, metformin improves insulin resistance [23,24], which has been recently
identified as a marker of adverse cardiac outcome [24,25]. Taken together these findings pro-
vide a rationale to determine whether metformin affects lipoprotein subfraction characteristics
in patients with an acute coronary event.
The Glycometabolic Intervention in Adjunct to Primary Percutaneous Coronary Interven-
tion in ST-Segment Elevation Myocardial Infarction (GIPS-III) trial was designed to evaluate
the effect of 4 months metformin treatment on left ventricular function in non-diabetic
patients with ST-segment elevation MI (STEMI) [26,27]. The rationale of this study is based on
experimental findings showing that metformin may beneficially affect left ventricular function
through activation of a number of intracellular pathways and alters mitochondrial function as
outlined extensively elsewhere [26]. Among other potentially beneficial effects, metformin may
also affect lipid and lipoprotein levels [26], which was a predetermined tertiary efficacy end-
point of the GIPS-III trial [26]. This randomized trial provides a framework to determine
effects of metformin on lipoprotein metabolism, and to evaluate associations of lipoprotein
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subfractions, obtained in the setting of an acute MI, with left ventricular ejection fraction
(LVEF) and infarct size assessed at 4 months.
The present anciliary analyses were initiated to test the extent to which metformin treat-
ment affects lipoprotein subfraction characteristics in GIPS-III participants. Second, we deter-
mined the association of lipoprotein subfractions with LVEF and infarct size.
Methods
Study population
The GIPS-III trial is has been registered as clinical trial with identifier: NCT01217307. The
design and primary results of the GIPS-III trial has been reported in detail elsewhere [26,27].
The inclusion and exclusion criteria of the GIPS-III stuy are reported in Table 1. In brief, 380
non-diabetic patients undergoing primary percutaneous coronary intervention (PCI) for
STEMI were randomized to receive a 4-month regimen with either metformin 500 mg twice
daily or matching placebo twice daily. During the PCI procedure, all patients except one pro-
vided verbal informed consent followed by written informed consent. This subject was
excluded, as well as were subjects in whom lipoprotein subfractions measurements were not
available. As a result, 185 subjects receiving metformin and in 186 subjects receiving placebo
were available for the current analyses. From these participants we determined lipoprotein sub-
fractions in 371 subjects at baseline, 338 subjects 24 hours post-MI and 317 subjects 4 months
post-MI. A total of 271 subjects completed 4 months follow-up evaluation by cardiac magnetic
resonance imaging (MRI). From these subjects in 268 lipoprotein subfractions were deter-
mined at baseline, 250 subjects 24 hours post-MI and 257 4 subjects months post-MI.
Blood samples were obtained shortly after admission at the catheterization laboratory, after
24 hours post-MI and 4 months after randomization. Very low density lipoproteins (VLDL),
LDL and HDL particle profiles were determined at these 3 time points. Samples for glucose,
glycated hemoglobin (HbA1c), plasma total cholesterol, LDL cholesterol, HDL cholesterol,
Table 1. In- and exclusion criteria for the GIPS-III trial.
Inclusion criteria Exclusion criteria
The diagnosis acute MI deﬁned by chest pain
suggestive for myocardial ischemia for at least 30 min,
the time from onset of the symptoms less than 12 h
before hospital admission, and an ECG recording with
ST- segment elevation of more than 0.1 mV in 2 or
more leads
Prior MI
Verbal followed by written informed consent Diabetes
At least one stent sized  3.0 mm Creatinin >177 μ mol/L measured pre-PCI
Eligible for cardiac MRI-scan: Need for coronary artery bypass grafting
Body Mass Index <40 kg/m2 an estimated life-
expectancy of less than 6 months
Rescue PCI after thrombolytic therapy
no ferromagnetic metal objects in the body When subjects develop a condition which, in the
investigator’s judgment, precludes study therapy
no claustrophobia Inability to provide informed consent
Younger than 18 years
Contra-indication to metformin
an estimated life-expectancy of less than 6
months
Abberviations: MI: myocardial infarction; ECG: electrocardiogram; PCI: percutaneous coronary intervention;
MRI: magnetic resonance imaging
doi:10.1371/journal.pone.0145719.t001
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triglycerides, apolipoprotein (apo)B and apoA-I were obtained at the catheterization laboratory
and 4 months after randomization.
Laboratory Measurements
Serum and EDTA-anticoagulated plasma samples were stored at − 80°C until analyzed. Plasma
total cholesterol, LDL cholesterol and HDL cholesterol were measured by a direct quantitative
assay using cholesterol (PEG-) esterase and (PEG-) cholesterol oxidase on a Roche Modular P
autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA). Non-HDL cholesterol was calculated
as the difference between total cholesterol and HDL cholesterol. Triglycerides (TG) were quan-
tified using the LipoProfile-3 algorithm (LipoProfile-3 algorithm; LipoScience Inc. (now Lab-
corp Inc.), Raleigh, North Carolina, USA) [16]. Quantification of TG was accomplished by
converting NMR particle numbers to lipid mass concentration units, assuming that the lipo-
protein particles have normal lipid content. NMR-derived values correlate well with chemically
measured values. Apolipoprotein (apo) B and apoA-I were computationally estimated by the
use of the high-throughput 1H nuclear magnetic resonance (NMR) metabolomics platform of
Computational Medicine (Oulu, Finland) [28].
VLDL, LDL and HDL particle profiles were measured by NMR spectroscopy with the Lipo-
Profile-3 algorithm (LabCorp, Raleigh, North Carolina, USA), as described [16]. VLDL, LDL
and HDL subclasses were quantified from the amplitudes of their spectroscopically distinct lipid
methyl group NMR signals, and were expressed in concentration units, i.e. μmol/L or nmol/L.
The lipoprotein subfraction particle concentrations are considered to represent an estimate of
the respective lipoprotein particle numbers. Diameter range estimates were for VLDL: large
VLDL (including chylomicrons if present;> 60 nm), medium VLDL (35 to 60 nm) and small
VLDL (27 to 35 nm), for LDL: IDL (23 to 27 nm), large LDL (21.2 to 23 nm) and small LDL (18
to 21.2 nm), and for HDL: large HDL particles: 9.4 to 14 nm; medium HDL particles: 8.2 to 9.4
nm; small HDL particles: 7.3–8.2 nm. The VLDL, LDL and HDL particle concentrations were
calculated as the sum of the respective lipoprotein subclasses. Weighted-average VLDL, LDL
and HDL sizes were derived from the sum of the diameter of each subclass multiplied by its rela-
tive mass percentage based on the amplitude of its methyl NMR signal [16].
NT-proBNP was routinely measured with a sandwich immunoassay on a Roche Modular E
platform (Mannheim, Germany).
Cardiac Magnetic Resonance Imaging (MRI)
LVEF and infarct size were measured by cardiac magnetic imaging [29]. These outcome mea-
sures were assessed by MRI four months after infarction. Details of the imaging analysis has
been reported elsewhere [26,27]. An independent core laboratory (Image Analysis Center, Free
University Medical Center, Amsterdam, The Netherlands) evaluated the MRI scans and
assessed the primary efficacy measure, blinded for treatment allocation and clinical patient data.
Myocardial blush grade (MBG)
MBG was categorized as previously described [30]. A physician blinded to data analyzed coro-
nary angiograms.
Statistical analysis
R (version 3.02 or higher, http://www.r-project.org/) was used for statistical analyses. Values
for continuous variables that are normally distributed are presented as mean ± SD. Continuous
variables not normally distributed are presented as median and interquartile ranges (IQRs).
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Because not all lipoprotein subfractions were normally distributed (Shapiro-Wilk Normality
test, P< 0.05), they were normalized using rank-based inverse normal transformation across
all time points.
Pearson correlation coefficients were calculated from lipoprotein subfractions at 4 months
after acute MI, and plotted using the corrplot function of the corrplot package of R. The corre-
lation matrix is presented in S1 Fig.
The extent to which clinical parameters, laboratory values and lipoprotein subfraction mea-
surements between treatment (metformin and placebo) groups were significantly different at
the various time-points (baseline, i.e. at admission for MI, 24 hours post-MI and 4 months
post-MI) was determined after data normalization using unpaired T tests. Difference in medi-
cation use was assessed using a multinomial chi-squared test. None of the baseline lipoprotein
variables were significantly different between the treatment groups.
For this reason the statistical comparisons of in the main results were given as the P-values
of the unpaired T tests after 4 months of treatment in primary analysis. In addition, regression
models were used to examine the changes in lipoprotein subfractions between the two treat-
ment groups (placebo and metformin). In this analysis, the respective lipoprotein variable at 24
hours and after 4 months was the dependent variable with the following independent covari-
ates: treatment assignment, age at randomization, sex, body mass index (BMI), statin use at 4
months and the baseline lipoprotein subfraction of interest.
For routine laboratory values the significance level was set at P 0.01. In view of multiple
testing of lipoprotein subfraction data, a principal components (PCs) analysis was carried out
using the prcomp-function of R. The first 8 components explained 96% of the variation, of
which the first 5 components explained 84% of the variation in the data set (S1 File). On the
basis of the PCs, the multiple testing corrected significance level of lipoprotein subfractions
was set to P 0.05/8 components, equivalent to P 0.0063.
To examine the relationship between baseline laboratory values or lipoprotein subfraction lev-
els at different time points (baseline and 24 hours post-MI) with LVEF or infarct size (4 months
post-MI), linear regression models were used. In the primary analysis, LVEF or infarct size was
the dependent variable with baseline laboratory values or lipoprotein subfractions as the inde-
pendent variable. A secondary analysis was performed adjusting for baseline laboratory values or
lipoprotein subfractions, age at randomization, sex, baseline NT-proBNP concentration, treat-
ment allocation, MBG and statin use at 4 months which we considered to be relevant covariates.
Results
Clinical paramaters, MRI parameters and laboratory values
Table 2 summarizes clinical parameters, MRI parameters and laboratory measurements at
baseline and at 4 months after intervention. There were no significant differences in clinical
and laboratory characteristics between the two treatment groups at baseline. After 4 months of
intervention there was a significantly lower LDL cholesterol in the metformin group (2.1 [1.8–
2.4] mmol/L) group compared to the placebo group (2.2 [1.8–2.4 2.7] mmol/L); P = 0.01 after
adjustment for baseline LDL cholesterol, age at randomization, sex, BMI, and statin use at 4
months). In a sensitivity analysis we performed a logistic regression with reduction of LDL
cholesterol as dependent variable and metformin as independent variable; this also resulted in
a trend towards lower LDL cholesterol (β = -0.25; SE: 0.12; P = 0.04).
Plasma triglycerides were much lower in both groups at baseline compared to the values
after 4 months of follow-up (P< 0.001 for all comparisons), whereas total cholesterol, non-
HDL cholesterol, LDL cholesterol and apoB were higher at baseline than after follow-up of 4
months (P< 0.001 for all comparisons).
Effect of Metformin on Lipoproteins in Non-Diabetics with STEMI
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Effect of metformin treatment on lipoprotein subfractions
Table 3 and S2 Fig show the median values of lipoprotein subfraction levels and lipoprotein sizes
at baseline, 24 hours post-MI and 4 months post-MI. There were no significant differences
between the two treatment groups at baseline and 24 hours post-MI. After 4 months of treat-
ment, large LDL particles (270.5 [190.0–365.8] vs 170.0 [93.0–278] nmol/L and LDL size (20.3
[20.0–20.6] vs 20.5 [20.1–20.9] nm) were decreased in the metformin group compared to the
Table 2. Clinical-, MRI- and laboratory parameters by treatment group at baseline and after 4 months.
Baseline (Myocardial Infarction) 4 Months Treatment
Clinical parameters Placebo (n = 186) Metformin (n = 185) P Placebo (n = 160) Metformin (n = 157) P P**
Age, mean 58.72 ± 11.44 58.80 ± 11.82 0.95
Women, n (%) 48 (26%) 46 (25%) 0.83
Body Mass index, mean 27.0 ± 3.9 27.0 ± 3.8 0.92 27.4 ± 4.0 27.0 ± 4.0 0.37
Statin use, n (%) 15 (8%) 13 (7%) 0.70
Medication use at discharge 0.25 at 4 months 0.92
Statin, n (%) 185 (99%) 184 (99%) 150 (94%) 147 (94%)
Aspirin, n (%) 181 (97%) 178 (96%) 154 (96%) 146 (93%)
Thienopyridine, n (%) 186 (100%) 185 (100%) 157 (98%) 152 (97%)
Coumarine, n (%) 7 (4%) 13 (7%) 7 (4%) 12 (8%)
Beta-blocker, n (%) 181 (97%) 174 (94%) 150 (94%) 148 (94%)
ACE-inhibitor or ARB, n (%) 141 (76%) 153 (83%) 139 (87%) 140 (89%)
Calcium-channel blocker, n (%) 3 (2%) 9 (5%) 13 (8%) 11 (7%)
Aldosterone antagonist, n (%) 12 (7%) 25 (14%) 19 (12%) 25 (16%)
Laboratory values P P* P P**
Glucose (mmol/L) 8.4 (7.0–9.8) 8.2 (7.0–9.4) 0.93 0.93 5.6 (5.2–6.1) 5.6 (5.1–6.2) 0.94 0.90
HbA1c (%) 5.8 (5.6–6.0) 5.8 (5.6–6.1) 0.51 0.43 5.9 (5.7–6.1) 5.9 (5.6–6.0) 0.11 0.07
Creatinine (μmol/L) 72 (62.3–80) 72 (61.0–84.0) 0.66 0.69 79.5 (72–88.3) 79 (70.0–87.0) 0.65 0.49
Total Cholesterol (mmol/L) 5.4 (4.8–6.0) 5.3 (4.7–6.1) 0.87 0.87 3.9 (3.5–4.4) 3.8 (3.4–4.2) 0.07 0.06
LDL Cholesterol (mmol/L) 3.8 (3.3–4.4) 3.7 (3.1–4.4) 0.57 0.65 2.2 (1.8–2.7) 2.1 (1.8–2.4) 0.02 0.01
non-HDL Cholesterol (mmol/L) 4.2 (3.7–4.9) 4.2 (3.6–4.9) 0.98 0.97 2.7 (2.7–3.2) 2.6 (2.2–3.0) 0.16 0.11
HDL Cholesterol (mmol/L) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 0.94 0.97 1.2 (1.0–1.5) 1.1 (0.9–1.4) 0.14 0.09
Triglycerides (mmol/L) 0.69 (0.57–0.88) 0.69 (0.59–0.98) 0.22 0.20 1.38 (1.04–1.84) 1.44 (1.02–2.01) 0.12 0.31
ApoB (g/L) 0.79 (0.68–0.93) 0.80 (0.64–0.93) 0.87 0.95 0.76 (0.66–0.86) 0.74 (0.66–0.87) 0.68 0.48
ApoA-I (g/L) 1.26 (1.16–1.40) 1.29 (1.16–1.42) 0.38 0.36 1.33 (1.23–1.47) 1.30 (1.21–1.44) 0.11 0.17
NT-proBNP (ng/L) 78 (37–175) 84 (42–235) 0.31 0.27 167 (74–355) 163 (67–389) 0.47 0.65
Cardiac MRI parameters
LVEF, % (95% CI) NA NA 54.7 (53.4–56.1) 53 (51.5–54.6) 0.10
LVEDV, ml (95% CI) NA NA 194.1 (186.4–201.9) 194.6 (186.5–202.6) 0.94
LVESV, ml (95% CI) NA NA 89.8 (83.8–95.8) 93.6 (87.3–100.0) 0.39
LVEDM, g (95% CI) NA NA 101.6 (97.2–106.0) 102.0 (98.1–105.8) 0.91
Infarct size, % (95% CI) NA NA 8.8 (7.5–10.1) 8.8 (7.5–10.2) 0.97
Abbreviations: Apo: apolipoprotein; ARB: aldosterone receptor blocker; BMI: body mass index; HbA1c: glycosylated hemoglobin; HDL: high density
lipoproteins; LDL: low density lipoproteins; LVEF: left ventricular ejection fraction; LVEDV: left venticular end diastolic volume; LVESV: left ventricular end
systolic volume; LVEDM: left ventricular end diastolic mass; non-HDL: non-high density lipoproteins; NT-proBNP: N-terminal pro brain natriuretic peptide.
Baseline and 4 months data are presented as mean ± SD, median (interquartile range), and number (percentage) as appropriate. P-values for placebo vs.
Metformin by unpaired T tests. P-value* adjusted for age at randomization, sex, BMI. P-value** additionally adjusted for respective baseline laboratory
value and statin use at 4 months. Bold is P-value  0.01.
doi:10.1371/journal.pone.0145719.t002
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placebo group (P 0.001 for each). After correcting for their baseline values, age at randomiza-
tion, sex, BMI and statin use at 4 months, these differences remained significant P 0.001 for
each). Fig 1 illustrates the changes in the various lipoprotein subfractions on lipoprotein particle
size after 4 months of therapy with metformin compared to placebo. Remarkably, all VLDL sub-
fractions and VLDL size were much lower in both groups at baseline compared to 24 hours and
after 4 months of follow-up (P< 0.001 for all comparisons). Conversely, the LDL particle con-
centration, as well as the IDL and large LDL subfractions were higher at baseline than at after 4
months of follow-up (P< 0.001 for all comparisons). However, the HDL particle concentration
and HDL subfractions were unaffected by metformin administration.
Fig 1. Lipoprotein subfraction concentrations and size using NMR after 4 months according to treatment group (VLDL-P; LDL-P; HDL-P;
Lipoprotein size). Data are presented as median (interquartile range). P-values from unpaired—tests. P-value 0.0063 placebo vs. Metformin group.
doi:10.1371/journal.pone.0145719.g001
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Relationship baseline laboratory values with left ventricular ejection
fraction and infarct size
Table 4 shows the relationships of baseline laboratory values with LVEF and infarct size at 4
months post-MI. As reported previously [manuscript submitted] NT-proBNP at baseline was
negatively associated with LVEF 4 months post-MI (P = 0.008). Glucose level at baseline was
positively associated with infarct size (P = 0.001). After adjustment for age, sex, baseline NT-
proBNP level, treatment allocation and myocardial blush grade this relationship remained sig-
nificant (P = 0.003).
Relationship of lipoprotein subfraction levels at baseline and 24 Hours
post-MI with left ventricular ejection fraction and infarct size
Table 5 shows the relationships of lipoprotein subfraction levels at baseline and 24 hours with
LVEF and infarct size at 4 months after MI. None of the lipoprotein subfractions at baseline
were associated with LVEF or infarct size. The concentration of small HDL particles 24 hours
post-MI was positively associated with LVEF (P = 0.003) and negatively with infarct size
(P = 0.006). Furthermore, the total VLDL particle concentration (P = 0.003) and the medium
VLDL particle concentration (P = 0.001) 24 hours post-MI were both negatively associated with
infarct size. After adjustment for age, sex, baseline NT-proBNP level, treatment allocation, myo-
cardial blush grade and statin use, the relationship between small HDL particles and LVEF
(P = 0.005), and between the medium VLDL particle concentration with infarct size (P = 0.001)
remained significant. The association of the total VLDL particle concentration and of small
HDL particles with infarct size was not significant after adjustment for these covariates.
Discussion
We show here that 4 months metformin administration initiated directly after the acute phase
of MI is associated with slight reductions reduced LDL cholesterol without affecting apoB levels
in a large group of patients without previously established diabetes. Metformin decreased large
LDL particles by approximately 35% without a significant effect on small LDL particles. Conse-
quently, LDL size was also decreased. Metformin did not significantly affect plasma
Table 4. Relationship LVEF and infarct size at 4 months with baseline laboratory values.
LVEF β (95% CI) P P* Infarct Size β (95% CI) P P*
Glucose -1.024 (-2.051, 0.002) 0.050 0.073 1.577 (0.640, 2.514) 0.001 0.003
HbA1c 0.551 (-0.513, 1.615) 0.309 0.172 -0.230 (-1.219, 0.760) 0.648 0.417
Total Cholesterol -0.308 (-1.329, 0.712) 0.552 0.367 0.279 (-0.685, 1.243) 0.570 0.337
LDL Cholesterol -0.288 (-1.306, 0.730) 0.578 0.278 0.198 (-0.762, 1.158) 0.685 0.379
non-HDL Cholesterol -0.147 (-1.163, 0.869) 0.776 0.468 0.001 (-0.951, 0.953) 0.998 0.577
HDL Cholesterol -0.385 (-1.424, 0.653) 0.466 0.840 0.806 (-0.170, 1.782) 0.105 0.272
Triglycerides 0.520 (-0.626, 1.667) 0.372 0.544 -0.509 (-1.589, 0.571) 0.354 0.730
ApoB -0.381 (-1.417, 0.656) 0.470 0.475 -0.069 (-1.072, 0.935) 0.893 0.846
ApoA-I -0.448 (-1.416, 0.521) 0.364 0.494 0.255 (-0.670, 1.180) 0.588 0.701
NT-proBNP -1.383 (-2.405, -0.362) 0.008 0.745 (-0.217, 1.707) 0.128
Linear regression model of LVEF or infarct size with baseline laboratory values. Unadjusted coefﬁcients are shown. Abbreviations: Apo: apolipoprotein;
HbA1c: glycosylated hemoglobin; HDL: high density lipoproteins; LDL: low density lipoproteins; LVEF: left ventricular ejection fraction; non-HDL: non-high
density lipoproteins; NT-proBNP: N-terminal pro brain natriuretic peptide. P-value*: adjusted for age at randomization, sex, baseline NT-proBNP
concentration, treatment allocation, myocardial blush grade and statin use at 4 months. Bold is P-value  0.01.
doi:10.1371/journal.pone.0145719.t004
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triglycerides, VLDL characteristics, HDL cholesterol, apoA-I and HDL subfractions. In addi-
tion, we observed that small-sized HDL particles and medium-sized VLDL obtained after 24
hours were associated with higher LVEF and a smaller infarct size.
The present findings on plasma (apo)lipoproteins and lipoprotein subfraction characteris-
tics should be interpreted in the context of lipoprotein changes that occur in the setting of an
acute coronary syndrome [10,31]. Thus, LDL cholesterol spontaneously decreases shortly after
MI and rises again after several weeks [10,31]. In the current study, the LDL particle concentra-
tion was lower at 24 hours post-MI in both treatment groups, which could to at least in part be
attributed by the initiation of statin therapy in the vast majority of study participants. In addi-
tion, initiation of statin treatment largely explained lower levels of total cholesterol, LDL cho-
lesterol, non-HDL cholesterol, apoB and LDL subfractions after 4 months. These lipoprotein
changes were present irrespective of metformin treatment. Plasma triglycerides may acutely
Table 5. Relationship of LVEF and infarct size at 4 months with lipoprotein subfraction levels at baseline and 24 hours.
Baseline (Myocardial Infarction) 24 hours post Myocardial Infarction
LVEF β (95%
CI)
P P* Infarct Size β
(95% CI)
P P* LVEF β (95%
CI)







0.117 0.152 -0.573 (-1.553,
0.407)
0.251 0.531 1.719 (0.333,
3.105)
0.015 0.015 -1.875 (-3.107,
-0.643)
0.003 0.008
Large VLDL 0.257 (-0.942,
1.456)
0.673 0.601 -0.339 (-1.440,
0.762)
0.545 0.812 1.034 (-0.397,
2.466)
0.176 0.171 -1.278 (-2.567,
0.010)
0.052 0.086
Medium VLDL 0.852 (-0.384,
2.088)
0.176 0.179 -1.151 (-2.291,
-0.012)
0.048 0.100 1.731 (0.374,
3.089)
0.012 0.007 -2.186 (-3.407,
-0.965)
0.001 0.001
Small VLDL 0.667 (-0.229,
1.563)
0.144 0.190 -0.278 (-1.120,
0.565)
0.517 0.862 0.284 (-1.022,
1.590)
0.653 0.864 -0.089 (-1.276,
1.099)
0.883 0.820
VLDL Size 0.086 (-1.098,
1.270)
0.886 0.866 -0.294 (-1.379,
0.791)
0.594 0.701 0.550 (-0.741,
1.841)







0.896 0.586 0.076 (-1.027,
1.178)
0.893 0.549 0.431 (-0.816,
1.677)





0.891 0.796 -0.742 (-1.741,
0.258)
0.145 0.153 0.595 (-0.456,
1.646)
0.265 0.487 -0.234 (-1.195,
0.727)
0.632 0.903
Large LDL -0.996 (-2.063,
0.070)
0.067 0.028 1.069 (0.073,
2.065)
0.035 0.029 -0.438 (-1.720,
0.844)
0.500 0.212 1.076 (-0.097,
2.248)
0.072 0.041
Small LDL 0.762 (-0.138,
1.663)
0.097 0.101 -0.614 (-1.451,
0.223)
0.150 0.263 0.513 (-0.538,
1.563)
0.337 0.153 -0.885 (-1.825,
0.056)
0.065 0.064
LDL Size -1.065 (-2.174,
0.045)
0.060 0.024 1.125 (0.094,
2.155)
0.033 0.034 -0.432 (-1.526,
0.662)







0.737 0.462 -0.525 (-1.533,
0.483)
0.306 0.211 1.317 (0.110,
2.524)
0.031 0.051 -0.887 (-1.986,
0.211)
0.113 0.149
Large HDL particles 0.286 (-0.784,
1.357)
0.599 0.315 0.462 (-0.536,
1.460)
0.363 0.752 -0.264 (-1.301,
0.773)







0.705 0.782 -0.542 (-1.542,
0.458)
0.287 0.377 -0.651 (-2.030,
0.727)
0.352 0.352 0.594 (-0.641,
1.829)
0.344 0.244
Small HDL particles -0.264 (-1.382,
0.854)
0.642 0.888 0.127 (-0.922,
1.177)
0.811 0.985 2.315 (0.815,
3.814)
0.003 0.005 -1.913 (-3.273,
-0.554)
0.006 0.009
HDL Size 0.414 (-0.853,
1.681)
0.520 0.275 0.503 (-0.686,
1.693)
0.405 0.780 -0.439 (-1.432,
0.555)
0.505 0.644 0.367 (-0.530,
1.264)
0.421 0.670
Linear regression model of left ventricular ejection fraction (LVEF) or infarct size with lipoprotein subfractions as Baseline (MI) and 24 hours post-MI.
Unadjusted β coefﬁcients are shown. P-value is from univariate linear regression model. P-value* is from adjusted model for age at randomization, sex,
baseline NT-proBNP concentration, treatment allocation, myocardial blush grade and statin use at 4 months. Bold is P-value  0.0063.
doi:10.1371/journal.pone.0145719.t005
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decrease after an MI, followed by an increase above baseline after several days [10]. All partici-
pants received heparin before percutaneous coronary intervention mostly before arrival at the
hospital as part of routine medical care [32]. It is well known that heparin stimulates lipopro-
tein lipase, thereby increasing lipolysis [33]. Even a low dose of heparin lowers plasma triglyc-
erides acutely [34]. This explains our observation that plasma triglycerides were about 50%
lower at presentation compared to 4 months follow-up. The VLDL particle concentration was
even 5-fold lower at baseline vs, the levels obtained after 24 hours and after 4 months. On the
other hand, HDL cholesterol concentration has been reported to remain fairly constant during
the acute phase of MI [10,31]. Accordingly, we did not observe much change in the HDL parti-
cle concentration and in HDL subfraction levels 24 hours after manifestation of MI.
The effects of metformin when initiated during the acute phase of MI to reduce LDL choles-
terol and large LDL particles has not been described in previously. In comparison, one year
treatment with metformin dosed 850 mg administered twice daily decreases the LDL particle
concentration, small-sized LDL particles and slightly increases LDL size along with improve-
ment in insulin sensitivity in subjects with impaired glucose tolerance [22]. While metformin
increases small HDL particles in the non-acute setting [22], we did not found a change in small
HDL particles in the present study. It has also been shown that 18 months treatment with met-
formin at a dose of 850 mg twice daily does not significantly affect plasma total cholesterol,
LDL cholesterol, HDL cholesterol and triglycerides despite improvement in insulin sensitivity
in statin-using non-diabetic subjects with stable coronary heart disease [23]. These variable
results emphasize the relevance of participant selection, the circumstances of initiation of met-
formin treatment and possibly also of its dose and exposure time.
In the general population, an inverse relationship of HDL cholesterol with incident coro-
nary heart disease has been consistently reported [35,36]. Moreover, the relevance of HDL sub-
fractions for cardiovascular risk prediction has received considerable attention [6,9,12,17,28].
As yet, the importance of larger-sized compared to smaller-sized HDL particles for coronary
risk has not been unequivocally established, neither in the setting of population-based cohort
studies [9,12,17,28], nor in specific high risk populations [3,4,37]. Of further interest, low HDL
cholesterol as determined during an acute coronary syndrome may predict recurrent cardio-
vascular events [38]. More recently, it was reported that HDL-associated cholesterol esterifica-
tion is impaired in the acute setting of a coronary syndrome despite a lack of decrease in HDL
cholesterol [39], whereas HDL anti-inflammatory function rather than HDL cholesterol may
predict recurrent events [40]. In non-acute patients, impaired ability of HDL to remove choles-
terol from macrophage model cells associates more closely with incident coronary heart disease
than lower HDL cholesterol [41]. These findings emphasize the importance of HDL functional
properties for atheroprotection [10,42]. In the context of the GIPS-III trial it is also relevant
that a low HDL cholesterol concentration may represent a determinant of heart failure [43].
Experimental induction of apoA-I, HDL’s most abundant apolipoprotein, improves cardiac
remodeling after MI in mice [44], although HDL mimetic therapy was unsuccessful in improv-
ing cardiac outcome in humans [45]. In coronary artery disease patients, it has been cross-sec-
tionally determined that HDL cholesterol and smaller-sized HDL may confer higher LVEF
[3,46]. In the current report, we considered the metformin- and placebo-receiving participants
together since metformin did not affect LVEF [27]. After adjustment for treatment allocation
and other relevant covariates we demonstrated that increased concentrations of smaller-sized
HDL particles prospectively predict higher LVEF. These novel results agreement with the con-
cept that specific HDL subfractions could be pathophysiologically implicated in better cardiac
performance. The mechanisms responsible for this association remain to be more precisely
delineated. Among other possibilities, it could reflect the ability of certain HDL subfractions to
exert anti-oxidative properties or to stimulate endothelial function [10,26,42]. In addition,
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higher concentrations of medium VLDL were associated with smaller infarct size. As yet the
clinical implication of this association is unknown.
Several other methodological aspects of our study need to be considered. First, this random-
ized study was carried out in a considerable number of participants, making lack of power to
demonstrate effects of metformin on VLDL and HDL subfraction characteristics as determined
by NMR spectroscopy unlikely. Moreover, neither plasma triglycerides nor HDL cholesterol
and apoA-I levels after 4 months of follow-up changed in response to metformin administra-
tion. Second, inherent to the design of this study to randomize subjects shortly after arrival at
the hospital, plasma lipid measurements were not carried out in the fasting state. For logistic
reasons, non-fasting samples were also obtained during follow-up. However, given the pla-
cebo-controlled design of GIPS-III, it is unlikely that this approach materially affected our
results. Third, only 2% of participants experienced recurrent major adverse cardiac events, and
none of participants died during 4 months follow-up [27]. For this reason, associations of lipo-
protein subfractions with hard clinical end-points could not be assessed. Instead, LVEF at 4
months follow-up was chosen as the pre-specified primary endpoint of the GIPS-III trial, rea-
soning that left ventricular dysfunction is a prevalent complication of STEMI which prospec-
tively predicts poor cardiac outcome [26,27]. Fourth, only subjects without known diabetes
participated in the GIPS-III trial [18,19]. The positive correlation between glucose at admission
and MI size after 4 months, therefore, suggests that MI size may relate to stress hyperglycemia
encountered during the acute phase of MI [47].
In conclusion, the present study suggests that metformin treatment initiated directly after
the acute phase of MI elicits a small decrease in LDL cholesterol together with a decrease in
LDL size. Furthermore, higher medium VLDL and higher small HDL particle concentrations
may confer beneficial associations with increased LVEF and decreased infarct size, respectively.
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